

Study	Reason for exclusion
Abernethy 2010 <sup>1</sup>	Unable to separate PIF-ILD data
Abernethy 2003 <sup>2</sup>	Unable to separate PIF-ILD data
Addrizzo-Harris 2002 <sup>3</sup>	Unable to separate PIF-ILD data
Azuma 2005 <sup>4</sup>	No extractable data
Behera 1998 <sup>5</sup>	Subjective improvement, no outcome measurements used
Behr 1997 <sup>6</sup>	Unable to separate PIF-ILD data. No outcome measures used.
Bhattacharyya 2009 <sup>7</sup>	No appropriate outcome measures
Chapela 1986 <sup>8</sup>	No extractable data
Dimadi 2003 <sup>9</sup>	No appropriate outcome measures
Douglas 1998 <sup>10</sup>	No extractable data
Fasciolo 1994 <sup>11</sup>	Unable to separate PIF-ILD data
Ferreira 2006 <sup>12</sup>	Unable to separate PIF-ILD data
Ferreira 2009 <sup>13</sup>	Unable to separate PIF-ILD data
Flaherty 2001 <sup>14</sup>	Unable to separate out dyspnoea data
Glockl 2009 <sup>15</sup>	No extractable data
Gomez 2007 <sup>16</sup>	Incomplete study
Gross 1995 <sup>17</sup>	Unable to separate PIF-ILD data
Gunella 1991 <sup>18</sup>	Unable to separate PIF-ILD data
Janssen 2010 <sup>19</sup>	No extractable data
Jastrzebski 2006 <sup>20</sup>	Unable to separate out PIF-ILD data
Johnson 1989 <sup>21</sup>	Unable to extract dyspnoea data from paper
Kalra 2003 <sup>22</sup>	No appropriate outcome measures
Lanuza 2000 <sup>23</sup>	Unable to separate PIF-ILD data
Leung 1996 <sup>24</sup>	Unable to separate PIF-ILD data
Naji 2006 <sup>25</sup>	Unable to separate PIF-ILD data
Peters 1993 <sup>26</sup>	No appropriate outcome measures.
Raghu 2004 <sup>27</sup>	No extractable data
Rodrigue 2005 <sup>28</sup>	Unable to separate PIF-ILD data
Salhi 2010 <sup>29</sup>	Unable to separate PIF-ILD data
Scano 1981 <sup>30</sup>	Unable to separate PIF-ILD data
Selman 1998 <sup>31</sup>	No extractable data
Sharifabad 2010 <sup>32</sup>	Unable to separate PIF-ILD data
Stack 1972 <sup>33</sup>	No appropriate outcome measures
Sturani 1988 <sup>34</sup>	No appropriate outcome measures
Swinburn 1991 <sup>35</sup>	Unable to separate PIF-ILD data
Taniguchi 2010 <sup>36</sup>	No extractable data
TenVergert 1998 <sup>37</sup>	Unable to separate PIF-ILD data
Webb 2000 <sup>38</sup>	Not clear that any IPF patients are included.
Young 1989 <sup>39</sup>	No appropriate outcome measures
Ziesche 1999 <sup>40</sup>	No appropriate outcome measures
Zisman 2000 <sup>41</sup>	No extractable data

1. Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE, 2nd, Marcello J, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. *Lancet* 2010;376(9743):784-93.
2. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. *BMJ* 2003;327(7414):523-8.
3. Addrizzo-Harris DJ, Harkin TJ, Tchou-Wong KM, McGuinness G, Goldring R, Cheng D, et al. Mechanisms of colchicine effect in the treatment of asbestosis and idiopathic pulmonary fibrosis. *Lung* 2002;180(2):61-72.
4. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *American Journal of Respiratory & Critical Care Medicine* 2005;171(9):1040-7.
5. Behera D, Gupta D, Jindal SK. Response to steroid therapy in patients of idiopathic pulmonary fibrosis: a retrospective analysis. *The Indian journal of chest diseases & allied sciences* 1998;40 (3):163-69.
6. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *American Journal of Respiratory & Critical Care Medicine* 2011;183(6):788-824.
7. Bhattacharyya P, Nag S, Bardhan S, Acharya D, Paul R, Ghosh M, et al. The role of long-term doxycycline in patients of idiopathic pulmonary fibrosis: The results of an open prospective trial. *Lung India* 2009;26 (3):81-85.
8. Chapela R, Zuniga G, Selman M. D-Penicillamine in the therapy of fibrotic lung diseases. *International Journal of Clinical Pharmacology Therapy and Toxicology* 1986;24 (1):16-17.
9. Dimadi MA, Rapti A, Latsi P, Antoniou KM, Birba G, Trigidou R, et al. Preliminary results of a prospective, multicentre randomised study comparing interferon Gamma-1b (IFN-γ) and Colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) [Abstract]. *European Respiratory Journal*, 2003.
10. Douglas WW, Ryu JH, Swensen SJ, Offord KP, Schroeder DR, Caron GM, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. *American Journal of Respiratory & Critical Care Medicine* 1998;158(1):220-5.
11. Fasciolo G, Nicolini A, Vacca N, Viglierchio P. Efficacy and safety of moguisteine in comparison with levodropropizine in patients with cough associated with chronic obstructive pulmonary disease, lung cancer, or pulmonary fibrosis. *Curr Ther Res Clin Exp*, 1994:251-61.
12. Ferreira G, Feuerman M, Spiegler P. Results of an 8-week, outpatient pulmonary rehabilitation program on patients with and without chronic obstructive pulmonary disease. *Journal of Cardiopulmonary Rehabilitation* 2006;26(1):54-60.
13. Ferreira A, Garvey C, Connors GL, Hilling L, Rigler J, Farrell S, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. *Chest* 2009;135(2):442-7.
14. Flaherty KR, Toews GB, Lynch JP, 3rd, Kazerooni EA, Gross BH, Strawderman RL, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. *American Journal of Medicine* 2001;110(4):278-82.
15. Gloeckl R, Weber-Lange B, Halle M, Kenn K. Interval versus continuous training in patient with end stage lung disease before lung transplantation [Abstract]. *European Respiratory Society Annual Congress, Vienna, Austria, September 12-16, 2009*: [E1715].
16. Gomez O, Ramos C, LaPerriere A, Glassberg M, Jackson R. Vasodilator therapy exercise tolerance and oxidant stress in IPF patients [Abstract]. *European Respiratory Journal*, 2007:111s [P779].

Appendix 3 Potentially relevant excluded studies

17. Gross CR, Savik K, Bolman RM, 3rd, Hertz MI. Long-term health status and quality of life outcomes of lung transplant recipients. *Chest* 1995;108(6):1587-93.
18. Gunella G, Zanasi A, Massimo Vanasia CB. [Efficacy and safety of the use of levodropropizine in patients with chronic interstitial lung diseases]. *Clin Ter* 1991;136(4):261-6.
19. Janssen DJ, Spruit MA, Alsemgeest TP, Does JD, Schols JM, Wouters EF. A patient-centred interdisciplinary palliative care programme for end-stage chronic respiratory diseases. *International Journal of Palliative Nursing* 2010;16(4):189-94.
20. Jastrzebski D, Gumola A, Gawlik R, Kozielski J. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. *Journal of Physiology and Pharmacology* 2006;57 (SUPPL. 4):139-48.
21. Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. *Thorax*, 1989:280-8.
22. Kalra S, Utz JP, Ryu JH. Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis. *Mayo Clinic Proceedings* 2003;78(9):1082-88.
23. Lanuza DM, Lefaiver C, Mc Cabe M, Farcas GA, Garrity E, Jr. Prospective study of functional status and quality of life before and after lung transplantation. *Chest* 2000;118(1):115-22.
24. Raghu G. Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. *European Respiratory Journal* 2011;37(4):743-6.
25. Naji NA, Connor MC, Donnelly SC, McDonnell TJ. Effectiveness of pulmonary rehabilitation in restrictive lung disease. *Journal of Cardiopulmonary Rehabilitation* 2006;26(4):237-43.
26. Peters SG, McDougall JC, Douglas WW, Coles DT, DeRemee RA. Colchicine in the treatment of pulmonary fibrosis. *Chest* 1993;103 (1):101-04.
27. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis. *New England Journal of Medicine* 2004;350 (2):125-33.
28. Rodrigue JR, Baz MA, Widows MR, Ehlers SL. A randomized evaluation of quality-of-life therapy with patients awaiting lung transplantation. *American Journal of Transplantation* 2005;5 (10):2425-32.
29. Salhi B, Troosters T, Behaegel M, Joos G, Derom E. Effects of Pulmonary Rehabilitation in Patients With Restrictive Lung Diseases. *CHEST Journal* 2010;137(2):273-79.
30. Scano G, Molino-Lova R, Stendardi L. Effects of steroid therapy on diffuse fibrosing alveolitis. [Italian]. *Giornale Italiano della Malattie del Torace* 1981;35 (1):19-27.
31. Selman M, Carrillo G, Salas J, Padilla RP, Pérez-Chavira R, Sansores R, et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. *Chest*, 1998:507-12.
32. Sharifabad MA, Hurewitz A, Spiegler P, Bernstein M, Feuerman M, Smyth JM. Written disclosure therapy for patients with chronic lung disease undergoing pulmonary rehabilitation. *J Cardiopulm Rehabil Prev* 2010;30(5):340-5.
33. Stack BH, Choo-Kang YF, Heard BE. The prognosis of cryptogenic fibrosing alveolitis. *Thorax* 1972;27(5):535-42.
34. Sturani C, Galavotti V, Fabbri M, del Bufalo C, Galleri C, Ravaglia C, et al. Preliminary results of a single-blind, randomized trial of cyclosporine and corticosteroids in idiopathic pulmonary fibrosis (IPF) [abstract]. *European Respiratory Journal*, 1988:247s.
35. Swinburn CR, Mould H, Stone TN, Corris PA, Gibson GJ. Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease. *American Review of Respiratory Disease* 1991;143(5 Pt 1):913-5.
36. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. *European Respiratory Journal* 2010;35(4):821-9.

Appendix 3 Potentially relevant excluded studies

37. TenVergert EM, Essink-Bot ML, Geertsma A, van Enkevort PJ, de Boer WJ, van der Bij W. The effect of lung transplantation on health-related quality of life: a longitudinal study. *Chest* 1998;113(2):358-64.
38. Webb M, Moody LE, Mason LA. Dyspnea assessment and management in hospice patients with pulmonary disorders. *The American journal of hospice & palliative care* 2000;17 (4):259-64.
39. Young IH, Daviskas E, Keena VA. Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. *Thorax*, 1989:387-90.
40. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. *The New England journal of medicine*, 1999:1264-9.
41. Zisman DA, Lynch JP, 3rd, Toews GB, Kazerooni EA, Flint A, Martinez FJ. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. *Chest* 2000;117(6):1619-26.